SEE NEW DATA FROM THE RESPOND REAL-WORLD EFFECTIVENESS STUDY

PURAPLY®AM REAL-WORLD EVIDENCE

See how PuraPly AM supported healing in a variety of real-world studies.

86%

of all PuraPly AM-treated wounds demonstrated improvement in the wound bed condition:

INCREASEDHEALTHYGRANULATIONTISSUE

REDUCEDEXUDATE

READINESSFOR OTHERADVANCED SKINSUBSTITUTES

SEE MORE RESULTS FROM THE FULL STUDY 
  • Reduced wound area for 73.2% of wounds over 12 weeks
  • 36.6% achieved complete wound closure
  • 6.7 weeks was the mean time to closure

VIEW CASE SERIES 

Prior Therapies

103 weeks

PuraPly AM

12 weeks

After ~2 years of prior therapies in refractory chronic wounds, PuraPly AM reduced size or closed wounds in ≤12 weeks2

  • Two-thirds of the wounds healed with an average time to closure of 10 weeks after first application
  • Other wounds reached 100% granulation

VIEW CASE SERIES 

CONCLUSIONS

  • Improved wound bed condition
  • Improved area reduction
  • Supported wound closure

See Dr. Paula Pons explain the unique technologies of PuraPly AM that help to support healing.

SUPPORT FOR YOU AND YOUR PRACTICE

See how the Organogenesis Circle of Care program can help with billing issues and more, or contact an Organogenesis Tissue Regeneration Specialist to see how PuraPly AM can help your practice.

Contact us

Please refer to the PuraPly AM Instructions for Use for complete prescribing information.

REFERENCES:

  1. Bain MA, et al. J Comp Eff Res. 2020:9(10)691-703. doi:10.2217/cer-2020-0058
  2. Oropallo AR. Plast Reconstr Surg Glob Open. 2019;7:e2047.
  3. Lintzeris D, et al. Wounds. 2018;30(3):72-78.